(54) **T-PA MUTANTS RESISTANT TO INHIBITION BY THEIR COGNATE INHIBITORS**

GEGENÜBER EIGENEN INHIBITOREN RESISTENTE T-PA MUTANTEN

T-PA MUTANTS RESISTANTES VIS-A-VIS DE LEURS PROPRES INHIBITEURS

(73) Proprietor: **BOARD OF REGENTS, THE
UNIVERSITY OF TEXAS SYSTEM
Austin, Texas 78701 (US)**

(72) Inventors:
 • **SAMBROOK, Joseph, F.**
  **Dallas, TX 75229 (US)**
 • **MADISON, Edwin, L.**
  **Dallas,Texas 75235 (US)**
 • **GOLDSMITH, Elizabeth, J.**
  **Dallas, TX 75209 (US)**
 • **GETHING, Maryjane, H.**
  **Dallas, TX 75229 (US)**
 • **GERARD, Robert, D.**
  **Dallas, TX 75252 (US)**

(74) Representative: **Rickard, Timothy Mark Adrian
Brookes & Martin,
High Holborn House,
52/54 High Holborn
London WC1V 6SE (GB)**

 • NATURE, vol. 339, no. 6227, 29th June 1989,
pages 721-724, London, GB; E.L. MADISON et
al.: "Serpin-resistant mutants of human
tissue-type plasminogen activator"
 • ANN. REVIEW OF BIOCHEMISTRY, vol. 54, 1985,
pages 597-629, Annual Reviews Inc., Palo Alto,
US; G.K. ACKERS et al.: "Effects of site-specific
amino acid modification on protein interactions
and biological function"
 • TRENDS IN BIOTECHNOLOGY, vol. 1, no. 3,
1983, pages 80-84, Elsevier Science Publishers
B.V., Amsterdam, NL; W.H. RASTETTER:
"Enzyme engineering: Applications and
promise"
 • B. BARRETT et al. (eds.), "Proteinase
Inhibitors", published 1986 by Elsevier Science
Publishers BV (Biomedical Division)
(Amsterdam), see pages 403-420.
 • ANNUAL REVIEW OF BIOCHEMISTRY, volume
46, issued 1977 (IKRAUT), "Serine Proteases:
structure and Mechanism of Catalysis", see
pages 331-358.
 • THE JOURNAL OF BIOLOGICAL CHEMISTRY,
volume 261, n<SYMBOL
 • FEBS. Letters, volume 157 number 2, issued July
1983, (W. STRABBURGER et al.)"Adaptation of
plasminogen activator sequences to know
protease structures", see pages 219-223.
 • BIOCHEMISTERY, Vol. 26, Issued 1987 (W.E.
HOLMES ET AL.)" Characterization of
Recombinant Human-Antiplasmin and of
Mutants Obtained by Site-Directed Mutagenesis
of the reactive Site", see pages 5153-5140.

(56) References cited:
 **EP-A- 0 093 619**   **WO-A-90/02798**

EP 0 462 207 B1

- BIOCHEMISTRY, vol. 27, issued 1988 (P.J. BRAUN ET AL.)". Use of Site-Directed Mutagenesis to Investigate the Basis for the Specificity of Hirudin", see pages 6517-6522.
- THE JOURNAL OF CLINICAL INVESTIGATION, Volume 80, issued August 1987 (M. CSHAPIRA ET AL.) "Protection by Recombinant -Antitrypsin Ala Arg358 against Arterial Hypotention Induced by Factor XII Fragment", see pages 582-585.
- THE JOURNAL OF CLINICAL INVESTIGATION, Volume 76, issued December 1985, (M. SCHAPIRA et al.) Recombinant -Antitcypsin Pittsburgh (Met358 Arg) Is a Potent Inhibitor of Plasma Killikrein and Activated Factor XII Fragment" See pages 635-637.
- THE NEW ENGLAND JOURNAL OF MEDICINE, Volume 309, Issued 22 September 1983 (M.C. OWEN et al.) "Mutation of antitrypsin to antithrombin", See pages 694-698.

Remarks:
The file contains technical information submitted after the application was filed and not included in this specification

Description

## FIELD OF THE INVENTION

5    **[0001]**    The present invention relates to t-PA mutants that are resistant to inhibition by their cognate inhibitors, and genes that encode the same. The t-PA mutants are useful as, e.g., pharmacological agents.

## BACKGROUND OF THE INVENTION

10    I. Serine Proteases

**[0002]**    Serine proteases (E.C. 3.4.21) are the sub-sub class of endopeptidases that use serine as the nucleophile in peptide bond cleavage (Barrett, A.J., In: Proteinase Inhibitors, Ed. Barrett, A.J. et al, Elsevier, Amsterdam, pages 3-22 (1986); and Hartley, B.S., Ann. Rev. Biochem., 29:45-72 (1960)).

15    **[0003]**    Serine proteases are well known in the art and two superfamilies of serine proteases, i.e., the chymotrypsin superfamily and the Streptomyces subtilisin superfamily, have been observed to date (Barrett, A.J., In: Proteinase Inhibitors, Ed. Barrett, A.J. et al, Elsevier, Amsterdam, pages 3-22 (1986); and James, M.N.G., In: Proteolysis and Physiological Regulation, Ed. Ribbons, D.W. et al, Academic Press, New York, pages 125-142 (1976)).

**[0004]**    Examples of serine proteases of the chymotrypsin superfamily include tissue-type plasminogen activator
20    (hereinafter "t-PA"), trypsin, trypsin-like protease, chymotrypsin, plasmin, elastase, urokinase (or urinary-type plasminogen activator (hereinafter "u-PA")), acrosin, activated protein C, Cl esterase, cathepsin G, chymase and proteases of the blood coagulation cascade including kallikrein, thrombin, and Factors VIIa, IXa, Xa, XIa and XIIa (Barrett, A.J., In: Proteinase Inhibitors, Ed. Barrett, A.J. et al, Elsevier, Amsterdam, pages 3-22 (1986); Strassburger, W. et al, FEBS Lett., 157:219-223 (1983); Dayhoff, M.O., Atlas of Protein Sequence and Structure, Vol. 5, National Biomedical Research Foundation, Silver Spring, Maryland (1972); and Rosenberg, R.D. et al, Hosp. Prac., 21:131-137 (1986)).
25    **[0005]**    Some of the serine proteases of the chymotrypsin superfamily, including t-PA, plasmin, u-PA and the proteases of the blood coagulation cascade, are large molecules that contain, in addition to the serine protease catalytic domain, other structural domains responsible in part for regulation of their activity (Barrett, A.J., In: Proteinase Inhibitors, Ed. Barrett, A.J. et al, Elsevier, Amsterdam, pages 3-22 (1986); Gerard, R.D. et al, Mol. Biol. Med., 3:449-457 (1986); and
30    Blasi, F. et al, In: Human Genes and Diseases, Ed. Blasi, F., John Wiley & Sons, Ltd., pages 377-414 (1986)).

**[0006]**    The catalytic domains of all of the serine proteases of the chymotrypsin superfamily have both sequence homology and structural homology. The sequence homology includes the total conservation of:

(i) the characteristic active site residues (e.g., $Ser_{195}$, $His_{57}$ and $Asp_{102}$ in the case of trypsin);
35    (ii) the oxyanion hole (e.g., $Gly_{193}$, $Asp_{194}$ in the case of trypsin); and
(iii) the cysteine residues that form disulfide bridges in the structure (Hartley, B.S., Symp. Soc. Gen. Microbiol., 24:152-182 (1974)).

The structural homology includes:
40

(i) the common fold that consists of two Greek key structures (Richardson, J., Adv. Prot. Chem., 34:167-339 (1981));
(ii) a common disposition of catalytic residues; and
(iii) detailed preservation of the structure within the core of the molecule (Stroud, R.M., Sci. Am., 231:24-88 (1974)).

45    **[0007]**    A comparison of the sequences of the members of the chymotrypsin superfamily reveals the presence of insertions or deletions of amino acids within the catalytic domains (see for example, Figure 1). In all cases, these insertions or deletions map to the surface of the folded molecule and thus do not effect the basic structure of the molecule (Strassburger, W. et al, FEBS Lett., 157:219-223 (1983)).

50    II. Serine Protease Inhibitors

**[0008]**    Serine protease inhibitors are well known in the art and are divided into the following families: (i) the bovine pancreatic trypsin inhibitor (Kunitz) family, also known as basic protease inhibitor (Ketcham, L.K. et al, In: Atlas of Protein Sequence and Structure, Ed. Dayhoff. M.O., pages 131-143 (1978) (hereinafter "BPTI"), (ii) the Kazal family,
55    (iii) the Streptomyces subtilisin inhibitor family (hereinafter "SSI"), (iv) the serpin family, (v) the soybean trypsin inhibitor (Kunitz) family, (vi) the potato inhibitor family, and (vii) the Bowman-Birk family (Laskowski, M. et al, Ann. Rev. Biochem., 49:593-626 (1980); Read, R.J. et al, In: Proteinase Inhibitors, Ed. Barrett, A.J. et al, Elsevier, Amsterdam, pages 301-336 (1986); and Laskowski, M. et al, Cold Spring Harbor Symp. Quant. Biol., LII:545-553 (1987)).

[0009] Crystallographic data are available for a number of intact inhibitors including members of the BPTI, Kazal, SSI, soybean trypsin and potato inhibitor families, and for a cleaved form of the serpin alpha-1-antitrypsin (Read, R.J. et al, In: Proteinase Inhibitors, Ed. Barrett, A.J. et al, Elsevier, Amsterdam, pages 301-336 (1986)). Despite the fact that these serine protease inhibitors are proteins of diverse size and sequence, the intact inhibitors studied to date all have in common a characteristic loop extending from the surface of the molecule that contains the recognition sequence for the active site of the cognate serine protease (Levin, E.G. et al, Proc. Natl. Acad. Sci. USA, 80:6804-6808 (1983)). The structural similarity of the loops in the different serine protease inhibitors is remarkable (Papamokos, E. et al, J. Mol. Biol., 158:515-537 (1982)). Outside of the active site loop, the serine protease inhibitors of different families are generally unrelated structurally, although the Kazal family and Streptomyces subtilisin family of inhibitors display some structural and sequence similarity.

[0010] Many of the serine protease inhibitors have a broad specificity and are able to inhibit both the chymotrypsin superfamily of proteases, including the blood coagulation serine proteases, and the Streptomyces subtilisin superfamily of serine proteases (Laskowski, M. et al, Ann. Rev. Biochem., 49:593-626 (1980)). The specificity of each inhibitor is thought to be determined primarily by the identity of the amino acid that is immediately amino-terminal to the site of potential cleavage of the inhibitor by the serine protease. This amino acid, known as the $P_1$ site residue, is thought to form an acyl bond with the serine in the active site of the serine protease (Laskowski, M. et al, Ann. Rev. Biochem., 49:593-626 (1980)).

## A. The BPTI Family

[0011] Serine protease inhibitors belonging to the BPTI family include BPTI, snake venom inhibitor, inter-alpha inhibitor, and the A4 amyloid precursor A4695 (Laskowski, M. et al, Ann. Rev. Biochem., 49:593-626 (1980); Read, R. J. et al, In: Proteinase Inhibitors, Ed. Barrett, A.J. et al, Elsevier, Amsterdam, pages 301-336 (1986); and Ponte, P. et al, Nature, 331:525-527 (1988)). Examples of serine proteases and their cognate BPTI family inhibitors are listed in Table I below.

Table I

| Serine Protease | Cognate BPTI Inhibitor |
|---|---|
| Trypsin | BPTI Snaka venom inhibitor Inter-alpha inhibitor |
| (Unknown) | A4 amyloid precursor A4695 protease nexin II |

## B. The Kazal Family

[0012] Serine protease inhibitors belonging to the Kazal family include pancreatic secretory inhibitor, ovomucoid and seminal plasma acrosin inhibitor (Laskowski, M. et al, Ann. Rev. Biochem., 49:593-626 (1980); Read, R.J. et al, In: Proteinase Inhibitors, Ed. Barrett, A.J. et al, Elsevier, Amsterdam, pages 301-336 (1986); and Laskowski, M. et al, Cold Spring Harbor Symp. Quant. Biol., LII:545-553 (1987)). Examples of serine proteases and their cognate Kazal family inhibitors are listed in Table II below.

Table II

| Serine Protease | Cognate Kazal Inhibitor |
|---|---|
| Trypsin | Pancreatic secretory inhibitor Ovomucoid Seminal plasma acrosin inhibitor |
| Acrosin | Ovomucoid Seminal plasma acrosin inhibitor |

## C. The Streptomyces Subtilisin Inhibitor

[0013] Serine protease inhibitors belonging to the Streptomyces subtilisin inhibitor family include inhibitors obtained from Streptomyces albogriseolus and plasminostreptin (Laskowski, M. et al, Ann. Rev. Biochem., 49:593-626 (1980)). Examples of serine proteases and their cognate Streptomyces subtilisin class inhibitors are listed in Table III below.

Table III

| Serine Protease | Cognate SSI Inhibitor |
|---|---|
| Subtilisin BPN' | _Streptomyces albogriseolus_ inhibitor |
| Plasmin | Plasminostreptin |
| Trypsin | Plasminostreptin |

D. The Serpin Family

[0014]    Serine protease inhibitors belonging to the serpin family include the plasminogen activator inhibitors PAI-1, PAI-2 and PAI-3, CI esterase inhibitor, alpha-2-antiplasmin, contrapsin, alpha-1-antitrypsin, antithrombin III, protease nexin I, alpha-1-antichymotrypsin, protein C inhibitor, heparin cofactor II and growth hormone regulated protein (Carrell, R.W. et al, _Cold Spring Harbor Symp. Quant. Biol._, _52_:527-535 (1987); Sommer, J. et al, _Biochem._, _26_:6407-6410 (1987); Suzuki, K. et al, _J. Biol. Chem._, _262_:611-616 (1987); and Stump, D.C. et al, _J. Biol. Chem._, _261_:12759-12766 (1986)).

[0015]    The inhibition of serine proteases by serpins has been reviewed in Travis, J. et al. _Ann. Rev. Biochem._, _52_: 655-709 (1983); Carrell, R.W. et al, _Trends Biochem. Sci._, _10_:20-24 (1985); Sprengers, E.D. et al, _Blood_, _69_:381-387 (1987); and _Proteinase Inhibitors_, Ed. Barrett, A.J. et al, Elsevier, Amsterdam (1986).

[0016]    Examples of serine proteases and their cognate serpin inhibitors are listed in Table IV below.

Table IV

| Serine protease | Cognate Serpin Inhibitor |
|---|---|
| Activated protein C | Protein C inhibitor PAI-1 |
| CI esterase | CI esterase inhibitor |
| Cathepsin G | Alpha-1-antitrypsin<br>Alpha-1-antichymotrypsin |
| Chymase | Alpha-1-antichymotrypsin |
| Chymotrypsin | Alpha-1-antichymotrypsin<br>Alpha-2-antiplasmin Contrapsin |
| Coagulation factors (VIIa, IXa, Xa, XIa, XIIa) | Antithrombin III<br>CI esterase inhibitor |
| Elastase | Alpha-1-antitrypsin |
| Kallikrein | CI esterase inhibitor Alpha-1-antitrypsin |
| Plasmin | Alpha-2-antiplasmin |
| Thrombin | Antithrombin III Heparin cofactor II |
| t-PA | PAI-1, PAI-2, PAI-3 |
| Trypsin | Alpha-1-antitrypsin Growth hormone regulated protein |
| Trypsin-like protease | Protease nexin I |

Table IV (continued)

| Serine protease | Cognate Serpin Inhibitor |
|---|---|
| u-PA | PAI-1, PAI-2, PAI-3 |

### E. The Soybean Trypsin Inhibitor Family

[0017] A single example of the soybean trypsin inhibitor family, purified from soybeans, has been sequenced. Its complex with bovine pancreatic trypsin has been studied (Sweet, R.M. et al, Biochem., 13:4214-4228 (1974)).

### F. The Potato Inhibitor Family

[0018] Serine protease inhibitors belonging to the potato inhibitor family include inhibitors from potatoes, barley and leeches (Read, R.J. et al, In: Proteinase Inhibitors, Ed. Barrett, A.J. et al, Elsevier, Amsterdam, pages 301-336 (1986)). Examples of serine proteases and their potato inhibitors are listed in Table V below.

Table V

| Serine Protease | Potato Inhibitor |
|---|---|
| Chymotrypsin | Barley chymotrypsin inhibitor |
| Subtilisin Novo | Barley chymotrypsin inhibitor |
| Subtilisin Carlsberg | Leech inhibitor eglin |

### G. The Bowman-Birk Inhibitor Family

[0019] Serine protease inhibitors belonging to the Bowman-Birk inhibitor family include homologous proteins from legumes (Laskowski, M. et al, Ann. Rev. Biochem., 49:593-626 (1980)). Examples of serine proteases and their Bowman-Birk inhibitors are listed in Table VI below.

Table VI

| Serine Protease | Bowman-Birk Inhibitor |
|---|---|
| Trypsin | Lima bean inhibitor IV |
| Elastase | Garden bean inhibitor |
| Chymotrypsin | Adzuki bean inhibitor II |

### III. Serine Protease-Inhibitor Complexes

[0020] Serine protease inhibitors of all families form stable 1:1 complexes with their cognate serine proteases. These complexes dissociate only slowly (hours to days) (Laskowski, M. et al, Ann. Rev. Biochem., 49:593-626 (1980); and Levin, E.G., Proc. Natl. Acad. Sci. USA, 80:6804-6808 (1983)). For all serine protease inhibitors, except the serpins, the dissociation products are a mixture of the intact and cleaved inhibitor molecules. On the other hand, since dissociation of serine protease-serpin complexes appears to yield only cleaved inhibitor molecules, serpins are thought to utilize a mechanism somewhat distinct from that of the other serine protease inhibitors.

[0021] Structural data are available for several serine protease-inhibitor complexes, including trypsin-BPTI, chymotrysin-ovomucoid inhibitor, chymotrypsin-potato inhibitor, and Streptomyces subtilisin-Streptomyces subtilisin inhibitor (Read, R.J. et al, In: Proteinase Inhibitors, Ed. Barrett, A.J. et al, Elsevier, Amsterdam, pages 301-336 (1986)). Examination of these structures reveals remarkable similarities in the specific interactions between each inhibitor and its cognate serine protease, despite the diverse sequences of the inhibitors. This structural similarity has suggested in the present invention that even when crystal structures are not available, it may be possible to predict the amino acid interactions occurring between an inhibitor and its cognate serine protease.

[0022] As discussed above, the inhibitors contain a reactive center that serves as a competitive substrate for the active site of the serine protease. Attack on the peptide bond between the $P_1$-$P_1'$ residues of the reactive center (e.g.,

$Arg_{346}$-$Net_{347}$ in the case of PAI-1) does not lead to the normal, rapid dissociation of the products from the serine protease but, rather, to the establishment of a stable serine protease-inhibitor complex, probably by formation of a covalent bond between the serine of the active site of the protease and the $P_1$ residue of the inhibitor (Laskowski, M. et al, Ann. Rev. Biochem., 49:593-626 (1980)). This mechanism indicates that the reactive center of an inhibitor, such as PAI-1, must fit tightly and precisely into the active site of the serine protease. However, to date, there are no X-ray crystallographic data on PAI-1, its cognate serine protease, t-PA, or the t-PA/PAI-1 complex. Thus, the exact nature of the interactions between this pair of proteins is unknown. There is a similar lack of structural information about other serpins or serpin-serine protease complexes.

IV. Utility of Serine Proteases

[0023]   A particularly important serine protease of the chymotrypsin superfamily is t-PA. t-PA is currently being used, via intracoronary or intravenous administration, to treat myocardial infarction, pulmonary embolism, and deep venous thrombosis, although it does not work directly to dissolve thrombi (blood clots). Rather, t-PA promotes cleavage of the peptide bond between $Arg_{560}$ and $Val_{561}$ of plasminogen (Robbins, K.C. et al, J. Biol. Chem., 242:2333-2342 (1967)), thereby converting the inactive zymogen into the powerful but non-specific protease, plasmin, which then degrades the fibrin mesh work of the blood clot (Bachmann, F. et al, Semin. Throm. Haemost., 43:77-89 (1984); Gerard, R.D. et al, Mol. Biol. Med., 3:449-557 (1986); and Verstraete, M. et al, Blood, 67:1529-1541 (1986)). t-PA produces local fibrinolysis without necessarily depleting systemic fibrinogen. This is because t-PA has the ability to bind directly to fibrin, forming a fibrin-t-PA complex whose affinity for plasminogen is increased approximately 500 fold (Ranby, M. et al, Biochim. Biophys. Acta, 704:461-469 (1982); and Rijken, D.C. et al, J. Biol. Chem., 257:2920-2925 (1982)). Thus, binding of intravenously-administered t-PA to coronary thrombi, where plasminogen is also present in high concentration (Wiman, B. et al, Nature, 272:549-550 (1978)), results in efficient production of plasmin at the site of the thrombus where it will do the most good.

[0024]   At present, t-PA is administered in the form of an initial bolus that is followed by sustained infusion. The total amount of enzyme administered during a standard 3 hour treatment is generally about 50-100 mg. Such large amounts are apparently required for two reasons: first, to counterbalance the effects of rapid clearance of t-PA from the circulation by hepatic cells (Krause, J., Fibrinolysis, 2:133-142 (1988)), and second, to overcome the effects of comparatively high concentrations of serine protease inhibitors that are present in plasma and platelets (Carrell, R.W. et al, In: Proteinase Inhibitors, Ed. Barrett, A.J. et al, Elsevier, Amsterdam, pages 403-420 (1986)).

[0025]   The major physiological inhibitor of t-PA is the serpin, PAI-1, a glycoprotein of approximately 50 kd (Pannekoek, H. et al, EMBO J., 5:2539-2544 (1986); Ginsberg, D. et al, J. Clin. Invest., 78:1673-1680 (1980); and Carrell, R. W. et al, In: Proteinase Inhibitors, Ed. Barrett, A.J. et al, Elsevier, Amsterdam, pages 403-420 (1986)). PAI-1 has been implicated as the cause of reduced fibrinolytic capacity of plasma from survivors of myocardial infarctions (Hamsten, A. et al, New Eng. J. Med., 313:1557-1563 (1985)). In addition, PAI-1 is an acute phase reactant and the elevated levels associated with myocardial infarction may attenuate the fibrinolytic activity of substantial amounts of the t-PA remaining in the plasma after therapeutic infusion of the t-PA (Lucore, C.L. et al, Circ., 77:660-669 (1988)). The second-order rate constant for association of PAI-1 with t-PA is extremely high (Hekman, C. et al, Arch. Biochem. Biophys., 262:199-210 (1988)) and accounts for the initial, "fast-phase" inhibition of t-PA by human plasma (Colucci, M. et al, J. Lab. Clin. Med., 108:53-59 (1986)). The rapid neutralization of t-PA by PAI-1 in vivo, may therefore contribute to coronary restenosis after thrombolytic therapy, a complication that affects between 10% and 35% of patients treated for acute myocardial infarction (Chesebro, J.H. et al, Circ., 76:142-154 (1987)).

[0026]   Although the association constants of other serpins, such as CI esterase inhibitor and alpha-2-antiplasmin, with t-PA are orders of magnitude lower than that of PAI-1 (Ranby, M. et al, Throm. Res., 27:175-183 (1982); and Hekman, C. et al, Arch. Biochem. Biophys., 262:199-210 (1988)), these serpins nevertheless bind to infused t-PA (Lucore, C.L. et al, Circ., 77:660-669 (1988)) and may attenuate the beneficial pharmacological properties of t-PA.

[0027]   Besides t-PA and PAI-1, many other serine protease-serpin pairs are of great medical importance. For example u-PA, like t-PA, is useful in the treatment of myocardial infarction and is subject to inhibition by the same serine protease inhibitors as t-PA.

[0028]   Thrombin, the serine protease used topically to promote blood clotting of wounds, is a procoagulant. Its cognate serpin, antithrombin III, is an anti-coagulant that specifically inhibits a number of serine proteases that participate in the blood coagulation cascade, including thrombin and Factors IXa, Xa, XIa and XIIa (Heimburger, N. et al, In: Proceedings of the International Research Conference on Proteinase Inhibitors, Ed. Fritz, H. et al, Walter de Gruyter, New York, pages 1-22 (1971); Kurachi, K. et al, Biochem., 15:373-377 (1976); Kurachi, K. et al, Biochem., 16:5831-5839 (1977); and Osterud, B. et al, Semin. Thromb. Haemost., 35:295-305 (1976)). Antithrombin III has been used therapeutically to treat disseminated intravascular coagulation. The activation of protein C by thrombin results in the self-limitation of the blood coagulation process because activated protein C inactivates coagulation factors Va and VIIIa, and is itself inhibited by its cognate serpin, protein C inhibitor.

[0029] Kallikrein, which functions to induce uterine contraction, to increase vascular permeability, and to initiate the intrinsic pathway of blood coagulation, is subject to inhibition by the serpin alpha-1-antitrypsin, one of the more important serpins.

[0030] Alpha-1-antitrypsin also inhibits leukocyte elastase and cathepsin, as well as trypsin, chymotrypsin and plasmin (Heimburger, N. et al, In: Proceedings of the International Research Conference on Proteinase Inhibitors, Ed. Fritz, H. et al, Walter de Gruyter, New York, pages 1-47 (1971); Janoff, A., Am. Rev. Resp. Dis., 105:121-127 (1972); and Ohlsson, K. et al, Eur. J. Biochem., 36:473-481 (1973)). The genetic deficiency of alpha-1-antitrypsin is directly related to emphysema (Carrell, R.W. et al, Trends Biochem. Sci., 10:20-24 (1985)) and alpha-1-antitrypsin replacement therapy has been used to treat emphysema (Marx, J.L., Science, 243:315-316 (1989)).

[0031] WO 90/02798 published 22 March 1990 describes t-PA mutants with substitutions of arginine at position 298 or 299 with alanine and disclaims certain t-PA mutants in the 296-302 region of t-PA.

## SUMMARY OF THE INVENTION

[0032] Accordingly, an object of the present invention is to improve t-PA, by protein engineering, so as to increase its resistance to inhibition by its cognate inhibitor.

[0033] Another object of the present invention is to provide genes encoding improved t-PA.

## BRIEF DESCRIPTION OF THE DRAWINGS

[0034] Figure 1 shows a comparison of the sequences of various serine proteases of the chymotrypsin superfamily. The sequences are aligned so as to demonstrate overlap of conserved amino acids. The numbers above trypsin refer to the numbering system used in the PDB3ptp.ent entry in the Protein Data Bank. The numbers above t-PA refer to the amino acids in the mature t-PA molecule.

[0035] Figure 2 shows a comparison of the sequences of various members of the serpin family of serine protease inhibitors. The sequences are aligned so as to demonstrate overlap of conserved amino acids. The numbers below alpha-1-antitrypsin and the numbers above PAI-1 refer to amino acid residues in the mature molecules.

[0036] Figure 3 schematically illustrates the construction of the vectors employed to mutate and express the wild-type t-PA and the serpin-resistant mutants of t-PA.

[0037] Figure 4 shows a comparison of the activities of wild-type t-PA and serpin-resistant mutants of t-PA in an indirect chromogenic assay. In Figure 4, $\square$ represents wild-type t-PA, o represents t-PA($R_{304}$->S), $\square$ represents t-PA ($R_{304}$->E), and • represents t-PA(Del$_{296-302}$).

[0038] Figure 5 shows the effect of PAI-1 on the activities of wild-type t-PA and serpin-resistant mutants of t-PA in an indirect chromogenic assay. In Figure 5, ■ represents wild-type t-PA, o represents t-PA($R_{304}$->S), $\square$ represents t-PA($R_{304}$->E), and • represents t-PA(Del$_{296-302}$).

[0039] Figure 6 shows a comparison of the activities of wild-type t-PA and serpin-resistant mutants of t-PA in an indirect chromogenic assay. In Figure 6, $\square$ represents t-PA($H_{297}$->Y), • represents wild-type t-PA, + represents t-PA ($K_{296}$->E), ■ represents the triple mutant t-PA($K_{296}$, $R_{298}$, $R_{299}$->E, E, E), ▲ represents t-PA($R_{299}$->E), Δ represents t-PA($R_{298}$->E) and o represents t-PA($P_{301}$->G).

[0040] Figure 7 shows the effect of PAI-1 on the activities of wild-type t-PA and serpin-resistant mutants of t-PA in an indirect chromogenic assay. In Figure 7, $\square$ represents t-PA($H_{297}$->Y), • represents wild-type t-PA, + represents t-PA($K_{296}$->E), ■ represents t-PA($K_{296}$, $R_{298}$, $R_{299}$->E, E, E), ▲ represents t-PA($R_{299}$->E), Δ represents t-PA($R_{298}$->E) and o represents t-PA($P_{301}$->G).

[0041] Figure 8 schematically illustrates the construction of the vectors employed to mutagenize and express the wild-type PAI-1 and the mutants of PAI-1.

## DETAILED DESCRIPTION OF THE INVENTION

[0042] According to the invention there is provided a t-PA mutant which is resistant to inhibition by its cognate inhibitor wherein in said t-PA mutant at least one of the basic amino acid at position 298 of human t-PA and the basic amino acid at position 299 of human t-PA has been replaced by an acidic or neutral amino acid.

[0043] In said t-PA mutant the basic amino acid at position 296 of human t-PA may also be replaced by an acidic or neutral amino acid.

[0044] In said mutant the basic amino acid at each of positions 296, 297, 298 and 299 of human t-PA may be replaced by an acidic or neutral amino acid.

[0045] The cognate inhibitor can be selected om PAI-1, PAI-2 and PAI-3.

[0046] According to the invention there is also provided a gene encoding a t-PA mutant of the invention.

[0047] According to the invention there is provided a method for obtaining a t-PA mutant which is resistant to inhibition

by its cognate inhibitor comprising:

(A) culturing a host cell with DNA comprising a gene of the invention and
(B) isolating the resulting t-PA mutant.

[0048]    According to the invention there is further provided a method for providing a t-PA mutant of the invention comprising:

(A) obtaining a t-PA mutant wherein at least one of the basic amino acid at position 298 of human t-PA and the basic amino acid at position 299 of human (t-PA has been replaced by an acidic or neutral amino acid; and
(B) screening for a t-PA mutant which is resistant to inhibition by its cognate inhibitor.

[0049]    According to the invention there is provided E. coli pSVT(R1⁻)/t-PA($R_{298} \rightarrow E$) [DH-1] having ATCC deposit No. 68157 or

E. coli pSTE/t-PA ($R_{299} \rightarrow E$) [DH-1] having ATCC deposit No. 68154, or
E. coli pSTE/t-PA ($K_{296}$, $R_{298}$, $R_{299} \rightarrow E,E,E$) [DH-1] having ATCC deposit No. 68153

[0050]    According to the invention there is provided

Plasmid pSVT7(R1⁻)/t-PA($R_{298} \rightarrow E$) present in E. coli microorganism pSTV7(R1⁻)/t-PA ($R_{298} \rightarrow E$) [DH-1] having ATCC deposit No. 68157 or
plasmid pSTE/t-PA ($R_{299} \rightarrow E$) present in E. coli microorganism pSTE/t-PA ($R_{299} \rightarrow E$) [DH-1] having ATCC deposit No. 68154 or
plasmid pSTE/t-PA ($K_{296}$, $R_{298}$, $R_{299} \rightarrow E,E,E$) present in E. coli microorganism pSTE/t-PA ($K_{296}$, $R_{298}$, $R_{299} \rightarrow E,E,E$) [DH-1] having ATCC deposit No. 68153

[0051]    All known serine protease inhibitors are structurally homologous in their reactive center loop and form similar interactions with their cognate serine proteases (Read, R.J. et al, In: Proteinase Inhibitors, Ed. Barrett, A.J. et al, Elsevier, Amsterdam, pages 301-336 (1986)). The structural correspondences between serine proteases and serine protease inhibitors can be used to build models of complexes that have not been studied heretofor.
[0052]    Because of the high degree of structural homology between the catalytic domain of t-PA and other serine proteases (Blundell, T. et al, Nature, 326:347-352 (1987)), it was postulated in the present invention that the known structure of the complex between trypsin and BPTI (Huber, R. et al, J. Mol. Biol., 89:73-101 (1974)); and Bode, W. et al, In: Proteolysis and Physiological Regulation, Academic Press, New York, pages 43-76 (1976)) might serve as a model for the interaction between t-PA and PAI-1. Other than the amino acids in the major recognition site, the amino acids of trypsin that make direct contact with BPTI are located in two separate regions of the polypeptide chain (residues 37-41 and 210-213) (see Figure 1).
[0053]    The region around amino acid residues $_{214}SWGS_{217}$ is highly conserved among all members of the chymotrypsin superfamily. By contrast, the region around amino acid residues $_{36}NSGYHF_{41}$ is more variable and forms part of the surface that interacts with the inhibitor. As shown in Figure 1, the amino acid sequence of t-PA in this region differs from that of trypsin in two major respects. First, the Tyr ($Y_{39}$) residue of trypsin has been replaced with an Arg ($R_{304}$) residue in t-PA. Modelling based on the assumption that the interaction between t-PA and PAI-1 mimics that between trypsin and BPTI suggests that $R_{304}$ of t-PA can form a salt bridge with a Glu ($E_{350}$) residue of PAI-1. This Glu residue in PAI-1 is equivalent in position to $I_{19}$ of BPTI (Table VII below) which forms a van der Waal's contact with $Y_{39}$ of trypsin (Huber, R. et al, J. Mol. Biol., 89:73-101 (1974)); and Bode, W. et al, In: Proteolysis and Physiological Regulation, Academic Press, New York, pages 43-76 (1976)). Therefore, $E_{350}$ of PAI-1 is predicted to form an ion pair with $R_{304}$ of t-PA.

**Table VII**

|         | P1    | P4' |     |
|---------|-------|-----|-----|
|         | 12    | .   | 24  |
| BPTI    | GPCKARIIRYFYN |  |  |

|         | 343   |     | 355 |
|---------|-------|-----|-----|
| PAI-1   | VSARMAPEEIIMD |  |  |

|         | 557   |     | 569 |
|---------|-------|-----|-----|
| PLG     | CPGRVVGGCVAHP |  |  |

Second, t-PA carries an additional stretch of seven amino acids ($_{296}$KHRRSPG$_{302}$, see Figure 1) located adjacent to predicted contact between t-PA(R$_{304}$) and PAI-1(E$_{350}$). Four out of seven of these amino acids are positively-charged, . while the predicted complementary region of PAI-1($_{350}$EEIIMD$_{355}$) contains three negatively-charged residues. It was believed in the present invention that electrostatic interactions between these regions may play an important role in the formation or stabilization of complexes between t-PA and PAI-1. By contrast, such interactions could not occur when t-PA interacts with its substrate, plasminogen (PLG), which has no negatively-charged residues in the equivalent region (see Table VII above).

[0054]    Comparisons of sequences of various serine proteases of the chymotrypsin superfamily, such as those shown in Figure 1, can be used as a guide to design one or more mutations in the various serine proteases of the chymotrypsin superfamily so as to make them resistant to inhibition by their cognate wild-type inhibitors. Like t-PA, the other serine proteases of the chymotrypsin superfamily shown in Figure 1 differ from trypsin at the important contact residue (Y$_{39}$ of trypsin) and in containing insertions of variable size located adjacent to the contact residue. Thus, examples of candidates for mutation include:

(i) amino acid residues that, in other serine proteases, occupy the position equivalent to that of Tyr (Y$_{39}$) of trypsin (the residue that forms a contact with Ile (I$_{19}$) of BPTI and therefore plays an important role in the interaction between the two proteins). In plasmin for example, a Met (M) residue occupies the position equivalent to Y$_{39}$ of trypsin. Mutation of this Met residue to another amino acid with different properties, such as charge or size (Glu (E) for example) is expected to eliminate or reduce the susceptibility of plasmin to inactivation by antiplasmin, although the particular substitute amino acid employed is not critical to the present invention. Similarly, mutation of the Gln (Q) residue of thrombin (that occupies the position equivalent to Y$_{39}$ of trypsin) to another amino acid with different properties, such as charge or size (for example Asp (D)) is expected to eliminate or reduce the susceptibility of thrombin to inactivation by antithrombin III, although the particular substitute amino acid employed is not critical to the present invention; and

(ii) residues of other serine proteases of the chymotrypsin superfamily that are not present in trypsin and map near the active site as small insertions on the surface of the molecule (see Figure 1). For example plasmin contains an insert of 2 amino acids (RF) adjacent to the contact residue in a position equivalent to that occupied by $_{296}$KHRRSPG$_{302}$ of t-PA. Mutation by deletion or substitution of either or both of these two amino acids, or by insertion of small numbers of additional amino acids is expected to eliminate or reduce the interaction with the inhibitor without necessarily affecting the catalytic site of the serine protease. As another example, u-PA contains an insert of six amino acids (RHRGGS) adjacent to the contact residue in a position equivalent to that occupied by $_{296}$KHRRSPG$_{302}$ of t-PA. Mutation or deletion of these six residues is expected to reduce or eliminate the interaction with serine protease inhibitors in a manner similar to that observed for the mutant t-PA(Del$_{296-302}$).

[0055]    Similarly, the region of the serine protease inhibitors within the reactive center is quite variable and forms part of the surface that interacts with the serine protease. Comparisons of sequences of various serine protease inhibitors of the serpin family, such as those shown in Figure 2, can be used as a guide to design one or more mutations in the various serine protease inhibitors, and in particular, in members of the serpin family of serine protease inhibitors, so as to make them able to efficiently inhibit the serine protease inhibitor-resistant serine proteases of the chymotrypsin superfamily of the present invention. Like PAI-1, other serpin family members shown in Figure 2 differ in sequence in the important contact amino acid residues (E$_{350}$ of PAI-1) and contain insertions of variable size located adjacent to the contact residue (see Table VIII below).

## Table VIII

Serpin

| | | 344 | | P1-P1' | | | | | | | | | | | | | | | | 358 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| h PAI-1 | S A | - | R | M | A | P | E | E | - | - | - | - | - | I | I | M | D | R | P F |
| r PAI-1 | S A | - | R | M | A | P | T | E | - | - | - | - | - | M | V | L | D | R | S F |
| h PAI-2 | T G | - | R | T | G | H | G | G | - | - | - | P | Q | F | V | A | D | H | P F |
| h A1AT | I P | - | M | S | I | P | P | E | - | - | - | - | - | V | K | F | N | K | P F |
| b A1AT | I P | - | M | S | I | P | P | E | - | - | - | - | - | V | K | F | N | K | P F |
| m A1AT | V P | - | Y | S | M | P | P | I | - | - | - | - | - | L | R | F | D | H | P F |
| r GHRP | L - | - | K | S | L | P | Q | T | I | - | - | P | L | L | N | F | N | R | P F |
| h AChym | T L | - | L | S | A | L | V | E | T | R | T | I | - | V | R | F | N | R | P F |
| m Cntrps | G I | R | K | A | I | L | P | A | - | - | - | - | - | V | H | F | N | R | P F |
| h ATIII | A G | - | R | S | L | N | P | N | - | - | R | V | T | F | K | A | N | R | P F |
| h HCII | M P | - | L | S | T | Q | V | R | - | - | - | - | - | F | T | V | D | R | P F |
| h A2AP | S - | - | R | M | S | L | S | S | - | - | - | - | - | F | S | V | N | R | P F |
| h C1inh | A A | - | R | T | L | L | V | - | - | - | - | - | - | F | E | V | Q | Q | P F |
| h PCinh | T F | - | R | S | A | R | L | N | - | - | S | Q | R | L | V | F | N | R | P F |
| r Nex-1 | A - | - | R | S | S | P | P | W | - | - | - | - | - | F | I | V | D | R | P F |

(h=human; r=rat; b=baboon; and m=mouse)

[0056]   Thus, examples of candidates for mutation include:

(i) amino acid residues that, in other serine protease inhibitors, occupy the position (P4') equivalent to that of Glu ($E_{350}$) of PAI-1 (the residue that forms a contact with Arg($R_{304}$) of t-PA and therefore plays an important role in the interaction of the two proteins). In the present invention, the Glu residue of PAI-1($E_{350}$) has been mutated to Arg (R) in order to restore the electrostatic interaction which was disrupted by construction of the $R_{304} \rightarrow E$ mutation in t-PA. This specific mutation in the serpin has been constructed so as to be complementary to the mutation that was introduced in the serine protease which renders it resistant to inhibition by the wild-type serpin. This complementary $E_{350} \rightarrow R$ mutation in the serpin was specifically chosen to render the serpin capable of inhibiting the serine protease inhibitor-resistant serine proteases of the chymotrypsin superfamily of the present invention; however, the particular substitute amino acid employed is not critical to the present invention. For example, if the Met (M) residue in plasmin equivalent to $Y_{39}$ of trypsin (see Figure 1) were altered to another amino acid with different properties, such as charge or size (as the example given above, Glu (E)), and that mutant plasmin showed reduced susceptibility to inhibition by wild-type alpha-2-antiplasmin, then mutation of the P4' Ser (S) residue in alpha 2-antiplasmin, to another amino acid (Arg (R) for example) capable of interacting with the altered Glu residue in plasmin, is expected to restore the susceptibility of the mutant plasmin to inactivation by the mutant alpha-2-antiplasmin. Similarly, if the Gln (Q) residue of thrombin were altered to Asp (D), as in the example for mutation of thrombin given above, then mutation of the P6' Arg (R) residue of antithrombin III to Glu (E) is expected to restore susceptibility of the wild-type inhibitor-resistant thrombin to inhibition by the mutant anti-thrombin III; and

(ii) additional amino acid residues of other members of the various families of serine protease inhibitors within the reactive center that form part of the interaction surface with their cognate serine protease. These residues are shown in Table VIII above for the serpin family of serine protease inhibitors.

For example, alpha-2-antiplasmin contains the sequence SLSSFSVN in the reactive center in a position equivalent to the $_{348}$APEEIIMD$_{355}$ of PAI-1. Mutation by substitution of any of these eight amino acids or by insertion of small numbers

of additional amino acids is expected to restore the interaction with the serine protease provided that those substitutions or insertions are complementary in some property, such as charge or size or hydrophobicity, to the amino acid residues that were introduced into the serine protease, which originally rendered it resistant to the wild-type serpin.

[0057] Provided that at least one of the basic amino acids at positions 298 and 299 of human t-PA has been replaced by an acidic or neutral amino acid, the t-PA mutants of the present invention may also include point mutants, deletion mutants, addition mutants or mutants containing combinations of there types of mutations.

[0058] The t-PA of the present invention can be prepared, e.g., by the well known techniques of oligonucleotide-mediated mutagenesis (Zoller, M. et al, DNA, 3:479-488 (1984); Kunkel, T. et al, Proc. Natl. Acad. Sci. USA, 82:488-492 (1985); and Kunkel, T. et al, Current Protocols in Molecular Biology, Green Publishing Associates & Wiley Inter-science, New York (1987)). However, the precise method of preparing the mutation in the t-PA is not critical to the present invention.

[0059] The mutant t-PA of the present invention can be screened for those having the desired properties, i.e., serine protease activity yet resistance to inhibition by the cognate inhibitor, using well known assays, such as described in Lottenberg, R. et al, Meth. Enzymol., 80:341-361 (1981).

[0060] The administration of such mutated t-PA is believed to be of benefit in a variety of clinical and commercial applications. The mutated forms of t-PA of the invention are believed to be useful to extend the effective life of t-PA in the circulation of a patient with a thrombotic disorder where extended fibrinolysis is required.

[0061] The amount of mutant t-PA of the present invention to be administered in clinical applications will depend upon the particular mutant t-PA employed, the desired therapeutic effect of the t-PA, and on factors such as the sex, age, weight and physiological condition of the patient to whom the protease is to be administered. The amount of mutant t-PA to employ can be determined by routine experimentation.

[0062] The mutant t-PAs of the present invention should be administered as determined by tests in appropriate in vitro and in vivo models and in clinical trials. It is anticipated that the doses required will be between 10 and 1000-fold less than that which is required for wild-type t-PA.

[0063] The mutant t-PA of the present invention can be administered with any pharmaceutically acceptable carrier or diluent as is well known in the art, such as a physiological saline solution (Lucore, C.L. et al, Circ., 77:660-669 (1988); and Chesebro, J.H. et al, Circ., 76:142-154 (1987)).

[0064] The particular mode of administration of the mutant t-PA of the present invention is dependent on the particular application thereof. Examples of such modes of administration include intravenous or intraperitoneal injection, intracoronary infusion, topical application and aerosol inhalation.

[0065] The following examples are provided for illustrative purposes only.

## EXAMPLE 1 (COMPARATIVE)

### t-PA MUTANTS

A. Selection of t-PA Sites for Mutagenesis

[0066] To test the hypothesis that residues $Arg_{304}$ and ($_{296}$KHRRSPG$_{302}$) of t-PA interact with PAI-1, oligonucleotide-mediated mutagenesis was used to produce the three mutant forms of t-PA shown in Table IX below.

**Table IX**

| | |
|---|---|
| wild-type t-PA | FAKHRRSPGERFLC |
| t-PA(Arg$_{304}$->S) | FAKHRRSPGESFLC |
| t-PA(Arg$_{304}$->E) | FAKHRRSPGEEFLC |
| t-PA(Del$_{296-302}$) | FA.......ERFLC |

[0067] Mutant t-PA(Del$_{296-302}$) lacks the seven amino acid insertion discussed above which is not found in trypsin, and was constructed so as to completely remove a portion of the t-PA sequence which interacts with the cognate serine protease inhibitor, PAI-1. Mutants t-PA(R$_{304}$→S) and t-PA(R$_{304}$→E) contain substitutions of Ser and Glu, respectively, for Arg$_{304}$, and were chosen to selectively alter the positively-charged Arg residue and eliminate its interaction with

the cognate serine protease inhibitor, PAI-1. A variety of other substitutions can be made for $R_{304}$ which would produce a t-PA with reduced susceptibility to its cognate serine protease inhibitor due to a lack of charged-pair interaction. For example, point mutations that convert the positively-charged residues in the loop (residues 296-302) to negatively-charged or neutral amino acids would be predicted to prevent, reduce or destabilize the interaction between t-PA and
5   PAI-1. A similar result can be obtained by replacing $P_{301}$ with another amino acid, with the exception of Gly (G). Additionally, insertion mutations can be made between residues 304 and 305, or anywhere between residues 296 and 305, so as to insert a series of about 1-6 amino acids that will not interact properly with the PAI-1 residues. Different substitutions and/or combinations of substitutions, insertions and deletions would be expected to affect the interaction between t-PA and PAI-1 to different extents, thereby allowing a variety of t-PAs to be generated with properties appro-
10   priate for particular applications or clinical conditions.

## B. Oligonucleotide-mediated Mutagenesis of t-PA

[0068]   Oligonucleotide-mediated mutagenesis of t-PA was carried out essentially as described by Zoller, M. et al,
15   DNA, 3:479-488 (1984) as modified by Kunkel, T., Proc. Natl. Acad. Sci. USA, 82:488-492 (1985); and Kunkel, T. et al, Current Protocols in Molecular Biology, Green Publishing Associates & Wiley Interscience, New York (1987).
[0069]   First, plasmid pSVT7(RI⁻)/t-PA, which contains a cloned copy of the cDNA encoding full-length human t-PA, was prepared as described by Sambrook, J. et al, Mol. Biol. Med., 3:459-481 (1986). pSVT7(RI⁻)/t-PA is a derivative of pSVT7 (Bird, P.M. et al, J. Cell Biol., 105:2905-2914 (1987)) (see Figure 3).
20   [0070]   pSVT7 was constructed from pKC3. pKC3 is a derivative of pko (Van Doren, K. et al, J. Virol., 50:606-614 (1984)) in which the pBR322-derived sequences from the Aval site to the EcoRI site (which contain the origin of replication and the β-lactamase gene) have been replaced by those of pUC 8 (Messing, J., Meth. Enzymol., 101:20-78 (1983)). In addition, a polylinker has been inserted into the unique HindIII site and the PvuII site upstream of the SV40 origin has been converted into a ClaI site. Vector pSVT7 was obtained by inserting a 20 base pair fragment containing
25   a bacteriophage T7 RNA polymerase-specific promoter (Pharmacia Fine Chemicals, Piscataway, NJ) into the unique StuI site of pKC3. This StuI site lies within sequences derived from the early region of SV40 at nucleotide 5190 in the SV40 sequence and approximately 30 base pairs downstream from the point of initiation of the early transcript (Tooze, J. et al, DNA Tumor Viruses, Cold Spring Harbor Press, page 813 (1981)).
[0071]   Then, the single EcoRI site was removed from pSVT7 by filling the recessed 3'-ends with the Klenow fragment
30   of E. coli DNA polymerase. The resulting expression vector was designated pSVT7(RI⁻) (see Figure 3).
[0072]   Next, cDNA coding for wild-type t-PA was excised from plasmid pL611 (Sambrook, J. et al, Mol. Biol. Med., 3:459-481 (1986); provided by Genetics Institute, Boston, MA) and inserted into pSVT7(RI⁻). pL611 contains, immediately upstream from the initiating AUG codon of t-PA, a synthetic oligonucleotide that introduces cleavage sites for NcoI and BamHI. Approximately 280 base pairs downstream of the TGA termination codon, a BalI site lies within the
35   3' untranslated sequence of the t-PA cDNA. XbaI linkers were added to the approximately 1965 base pair NcoI-BalI fragment of t-PA DNA that was excised from plasmid pL611. This NcoI-BalI fragment contains the sequences that code for the complete t-PA protein but lacks sequences corresponding to (i) the distal 3'-untranslated region of t-PA mRNA and (ii) all of the 5'-untranslated sequences of t-PA mRNA, i.e., the sequences between a SalI site and the initiating ATG codon (Pennica, D. et al, Nature, 301:214-221 (1983)). The fragment of t-PA cDNA carrying XbaI sites at each
40   end (Sambrook, J. et al, Mol. Biol. Med., 3:459-481 (1986)) was used to generate pSVT7/t-PA (see Figure 3). The approximately 1970 base pair DNA fragment was excised from the resulting plasmid by digestion with XbaI, purified by 0.8% (w/v) agarose gel electrophoresis and inserted into the XbaI site of plasmid pSVT7(RI ) so that the sequences coding for the N-terminus of t-PA were placed immediately downstream of the bacteriophage T7 and SV40 early promoters. The resulting plasmid was designated pSVT7(RI⁻)/t-PA (see Figure 3).
45   [0073]   Then, pSVT7(RI⁻)/t-PA was digested to completion with EcoRI. The 472 base pair fragment (nucleotides 842-1314 which encodes the region covering amino acids 206 to 364) of t-PA was purified by 1.2% (w/v) agarose gel electrophoresis. This fragment was then ligated with replicative-form DNA of the bacteriophage M13 vector M13mp18 (Yanisch-Perron, C. et al, Gene., 33: 103-119 (1985)) which had previously been digested with EcoRI and dephosphorylated with calf intestinal alkaline phosphatase (see Figure 3).
50   [0074]   Unless otherwise specified, these and other standard recombinant DNA procedures described herein were carried out as described in (i) Maniatis, T. et al, Molecular Cloning: A Laboratory Manual, 1st Edition, Cold Spring Harbor (1982) and (ii) Meth. Enzymol., Volume 152, Ed. Berger, S. et al, Academic Press, New York (1987).
[0075]   The ligated DNA was transfected into E. coli strain TG-1 (Gibson, T., Thesis, University of Cambridge, England (1984)). White plaques formed by recombinant bacteriophages were picked and the presence of the appropriate 472
55   base pair EcoRI fragment was verified by restriction mapping, Southern hybridization and DNA sequencing.
[0076]   Mutations in the 472 base pair EcoRI fragment were introduced using a 5'-phosphorylated synthetic mutagenic primer as described by Kunkel, T. et al, Proc. Natl. Acad. Sci. USA, 82:488-492 (1985); and Kunkel T., Meth. Enzymol., 154:367-382 (1987)). The sequences of the three mutagenic primers employed to construct the t-PA mutants were:

t-PA(R$_{304}$->S)          5$'$ GCCCGGAGAGTCGTTCCTGTGC $^3$$'$

t-PA(R$_{304}$->E)          5$'$ GCCCGGAGAGGAGTTCCTGTGC $^3$$'$

t-PA(Del$_{296-302}$)          5$'$ GCCATCTTTGCCGAGCGGTTCCTG $^3$$'$

The above protocol uses a DNA template, produced in a strain of E. coli that is dut⁻, ung⁻, i.e., strain CJ236 (Kunkel, T. et al, Proc. Natl. Acad. Sci. USA, 82:488- 492 (1985); and Kunkel, T., Meth. Enzymol., 154:367-382 (1987)). The DNA template contains a small number of uracil residues in place of thymine.

[0077]    After the mutagenic primer was extended in vitro, the partially-filled circular DNA was transfected into a strain of E. coli that is dut⁺, ung⁺ , i.e., TG-1 (Gibson, T., Thesis, University of Cambridge, England (1984)). The uracil residues in the template strand were then removed in vivo by the action of the enzyme uracil N-glycosylase. This generated lethal lesions in the template strand and therefore allowed rapid and efficient recovery of mutants.

[0078]    More specifically, the uracil-containing template DNAs were annealed to the 5' phosphorylated mutagenic primers shown above. Extension of the primer was carried out for 12-16 hours at 15°C using the Klenow fragment of E. coli DNA polymerase. The newly-synthesized strand was ligated to the 5' end of the mutagenic primer with bacteriophage T4 DNA ligase, forming a circle bearing a mismatch. The resulting DNA was used to transfect E. coli strain TG-1 (Gibson, T., Thesis, University of Cambridge, England (1984)) and single-stranded DNA was prepared from a number of the plaques. These DNAs were completely sequenced. The double-stranded replicative form of the DNAs of proven mutants was then isolated and the mutated 472 base pair fragments were isolated by digestion with EcoRI and electrophoresis through 1.2% (w/v) agarose gels. As described in detail below, these fragments containing mutations were then used to reconstruct versions of the t-PA cDNA that encoded the t-PA mutants of interest.

## C. Construction of Expression Vectors for Mutant t-PAs

[0079]    Mutants of t-PA in plasmid pSVT7(RI⁻)/t-PA were constructed as follows: The central 472 base pair EcoRI fragment of t-PA cDNA was removed from plasmid pSVT7(RI⁻)/t-PA by digestion with EcoRI and by 1.2% (w/v) agarose gel electrophoresis. The remaining linear fragment of the plasmid DNA was then ligated to the versions of the 472 base pair fragment created by oligonucleotide-mediated mutagenesis (see Figure 3). The resulting plasmids were designated pSVT7(RI⁻)/t-PA(R$_{304}$→S), pSVT7(RI⁻)/t-PA(R$_{304}$→E) and psvT7(RI⁻)/t-PA(Del$_{296-302}$).

[0080]    E. coli strain DH-1 (Hanahan, D. et al, DNA Cloning, Volume 1, Ed. Glover, D.M., I.R.L. Press, Oxford, pages 109-135 (1985)) was transformed with the above mutant plasmids and the resulting strains were designated pSVT7 (RI⁻)/t-PA(R$_{304}$→S) [DH-1]; pSVT7(RI⁻)/t-PA(R$_{304}$→E) [DH-1]; and pSVT7(RI⁻)/t-PA(Del$_{296-302}$) [DH-1], respectively. The presence of the correct fragment was confirmed by hybridization to the appropriate radiolabeled mutagenic oligonucleotide and the orientation of the fragment was verified by restriction mapping and DNA sequencing, using the appropriate mutagenic oligonucleotides as primers.

pSVT7(RI⁻)/t-PA(R$_{304}$→S) [DH-1],
pSVT7(RI⁻)/t-PA(R$_{304}$→E) [DH-1]          and
pSVT7(RI⁻)/t-PA(Del$_{296-302}$) [DH-1] have been deposited at the American Type Culture Collection under ATCC Nos. 67894, 67896 and 67895, respectively.

## D. Transfection of COS Cells

[0081]    Next, approximately 10$^6$ COS cells (Gluzman, Y. et al, Cell, 23:175-182 (1981)) per 100 mm dish were transfected with 1.0 µg of the appropriate plasmid DNA purified by the alkaline lysis procedure (Maniatis, T. et al, Molecular Cloning: A Laboratory Manual, 1st edition, Cold Spring Harbor (1982)). More specifically, the medium was removed from the COS cells by aspiration and the monolayers were washed once with 5.0 ml of Dulbecco's medium (GIBCO, Inc.) containing 10 mM HEPES (pH 7.15) (Sigma Chemical Co.). After removal of the wash solution, the plasmid DNA was then added to the monolayers in a volume of 1.5 ml of wash solution containing 300 µg of DEAE-dextran (Pharmacia, Inc.). The monolayers were then incubated for 1 hour at 37°C in an humidified atmosphere containing 6.0% $CO_2$. The monolayers were agitated gently every 20 minutes during this period. After the monolayers had been exposed to the plasmid DNA for 1 hour, they were washed once with Dulbecco's medium containing 10 mM HEPES (pH 7.15)

and then 10 ml Dulbecco's medium containing 10% (v/v) fetal bovine serum (GIBCO, Inc.) and 100 µM chloroquine (Sigma Chemical Co.) was added. The monolayers were then incubated at 37°C for 4 hours as described above, and washed twice with 5.0 ml of Dulbecco's medium lacking fetal bovine serum but containing 10 mM HEPES (pH 7.15). 10 ml of Dulbecco's medium containing 10% (v/v) fetal bovine serum was then added and the monolayers were incubated at 37°C as described above for 12 hours. Then, the monolayers were washed three times each with 5.0 ml with Dulbecco's medium lacking fetal bovine serum and incubated at 37°C in the same medium for a further 36-60 hours. Mock-transfected cells were treated identically except that plasmid DNA was omitted from the solution containing DEAE-dextran. At the end of the incubation period, the supernatant medium was collected from the cells and analyzed as described below.

E. Quantitation of Wild-Type and Mutant t-PAs by Solid-Phase Radioimmunoassay

[0082]   A solid-phase radioimmunoassay was performed essentially as described for influenza hemagglutinin (Gething, M.J. et al, Nature, 293:620-625 (1981)) using the IgG fraction of rabbit antisera raised against purified human t-PA so as to quantitate the amounts of wild-type and mutant t-PAs produced in the COS cells. The concentration of t-PA determined by this method was between 0.5 and 1.0 µg/ml.

F. Enzymatic Assay of Wild-Type and Mutant t-PAs

[0083]   An indirect chromogenic assay was carried out so as to determine the activities of the wild-type and mutant t-PAs produced in the COS cells. In this assay, free p-nitroaniline is released from the chromogenic substrate Spectrozyme PL (H-D-norleucylhexahydrotyrosyl-lysine-p-nitroanilide diacetate salt) (American Diagnostica, Inc.) by the action of plasmin generated by the action of t-PA on plasminogen. The release of free p-nitroaniline was measured spectrophotometrically at $OD_{405}$ nm.

[0084]   More specifically, 100 µl reaction mixtures comprising 150-200 pg of the t-PA to be tested, 0.4 mM of Spectrozyme PL, 0.1 µM of Lys-plasminogen (American Diagnostica, Inc.) and 0.5-25 µg/ml of soluble fibrin (Des-A-fibrinogen) (American Diagnostica, Inc.) in a buffer comprising 50 mM Tris-HCl (pH 7.5), 0.1 M NaCl, 1.0 mM EDTA and 0.01% (v/v) Tween 80 were incubated at 37°C in 96-well, flat-bottomed microtiter plates (Costar, Inc.) and the $OD_{405}$nm was measured with a Bio-tek microplate reader (Model EL310) at 15 or 30 minute intervals over a 2 hour period. Aliquots of buffer or appropriately-diluted samples of medium from mock-transfected cells were analyzed as controls and the OD values obtained (<0.01 unit) were subtracted from the corresponding test values. Delta OD values were measured as the change in optical density between 30 minutes and 60 minutes, i.e., following the lag phase of the reaction and the complete conversion of single-chain t-PA to the two-chain form. Under the conditions used in the standard assay (0.1 µM of Lys-plasminogen and 25 µg/ml of Des-A-fibrinogen), soluble fibrin stimulated the activity of t-PA 20-40 fold. The results are shown in Figure 4.

[0085]   As shown in Figure 4, all three of the above-described t-PA mutants were found to be enzymatically active and their specific activities were not found to be significantly different from that of wild-type t-PA. In addition, the above-described t-PA mutants were found to respond to varying concentrations of Des-A-fibrinogen in a manner similar to that of wild-type t-PA. The maximal stimulation by Des-A-fibrinogen was 20-40 fold. This is in agreement with the observations of others on wild-type t-PA using a Des-A-fibrinogen preparation (Karlan, B. et al, Biochem. Biophys. Res. Comm., 142:147-154 (1987)). In each case, half-maximal stimulation occurred when Des-A-fibrinogen was present at a concentration of approximately 1.0 µg/ml.

[0086]   Next, the $K_m$ and $K_{cat}$ values of the wild-type and mutant t-PAs were determined by assaying the various forms of the enzyme in the presence of saturating concentrations of Des-A-fibrinogen (25 µg/ml) and different concentrations (from 0.02-0.16 µM) of the substrate, Lys-plasminogen. The results are shown in Table X below.

Table X

| Enzyme | $K_m(\mu M)$ | $K_{cat}(s^{-1})$ |
|---|---|---|
| Wild-type t-PA | 0.024 | 0.22 |
| t-PA($R_{304}\rightarrow$S) | 0.019 | 0.23 |
| t-PA($R_{304}\rightarrow$E) | 0.023 | 0.22 |
| t-PA($Del_{296\text{-}302}$) | 0.029 | 0.17 |

[0087]   As shown in Table X above, the $K_m$ and $K_{cat}$ values for the different t-PA mutants were similar to one another. The values are also similar to values for wild-type t-PA reported by Boose, J. et al, Biochem., 28:635-643 (1989); and Hoylaerts, M. et al, J. Biol. Chem., 257:2912-2919 (1982).

[0088]    The data shown in Figure 4 and Table X demonstrate that (i) deletion of amino acids 296-302 of t-PA and (ii) substitution of Ser or Glu for Arg at position 304 have little effect on the ability of t-PA to activate plasminogen and to be stimulated by soluble fibrin fragments.

[0089]    To test whether deletion of amino acids 296-302 and substitution of $Arg_{304}$ affects the interaction of t-PA with PAI-1, approximately 250 pg (3.8 femtomoles) each of the wild-type and mutant t-PAs were pre-incubated for 20 minutes with 0-480 femtomoles of partially-purified recombinant PAI-1. The residual enzymatic activity was then measured using the indirect chromogenic assay described above. The partially-purified recombinant PAI-1 was obtained as described in Example 2 below. The results are shown in Figure 5.

[0090]    As shown in Figure 5, all three of the t-PA mutants behave quite differently from wild-type t-PA. That is, under conditions where wild-type t-PA (■) is completely inhibited by PAI-1 (24 femtomoles of PAI-1), the deletion mutant t-PA($Del_{296-302}$) (•) retains approximately 95% of its activity. Only when high concentrations of PAI-1 are present (480 femtomoles of PAI-1), does mutant t-PA($Del_{296-302}$) (•) display any significant diminution of enzymatic activity. The two substitution mutants, i.e., t-PA($R_{304}{\rightarrow}S$) (o) and t-PA($R_{304}{\rightarrow}E$) (□), also are resistant to inhibition by PAI-1, although to different extents. Also, as shown in Figure 5, the two substitution mutants containing Ser or Glu instead of Arg require approximately 4 and 25 times more PAI-1, respectively, for half-maximal inhibition of enzyme activity than does wild-type t-PA.

[0091]    The above data indicate that amino acids 296-302 and 304 are not involved in catalytic functions of t-PA but play an important role in the interaction of the enzyme with its cognate serine protease inhibitor, PAI-1. Using the structure of trypsin as a model, these amino acids are predicted to map near the active site of the serine protease, some distance from the catalytic triad. Thus, the area of contact between t-PA and PAI-1 is more extensive than the interaction between t-PA and its true substrate plasminogen.

[0092]    In order to determine whether or not mutant t-PA($Del_{296-302}$) also exhibited resistance to the complex mixture of serine protease inhibitors present in human plasma, a 1:100 dilution of human plasma was substituted for the partially-purified recombinant PAI-1 in the protocol described above. Under these conditions, approximately 70% of the activity of the wild-type t-PA was inhibited while the activity of t-PA($Del_{296-302}$) was unaffected.

[0093]    In addition, wild-type t-PA and t-PA($Del_{296-302}$) were incubated with undiluted human plasma and then the mixtures were acidified to pH 5.0 and centrifuged for 5 minutes at 12,000 x g. The clarified supernatants were diluted and assayed for residual t-PA activity, which totalled 90% for the mutant t-PA($Del_{296-302}$) and 20% or less for the wild-type t-PA. The above results demonstrate that mutant t-PA($Del_{296-302}$) is resistant to the complex mixture of serine protease inhibitors present in human plasma and therefore is believed to be superior to wild-type t-PA as a therapeutic agent.

G. Additional t-PA Mutants

[0094]    The data presented in Section F above demonstrate that residues 296-302 and 304 of t-PA play an important role in interaction of the enzyme with the cognate inhibitor, PAI-1, but not with the substrate, Lys-plasminogen. Modeling of the catalytic domain of t-PA based on the known structure of trypsin suggests that residues 296-302 form a surface loop at the edge of the enzyme's active site. This loop is highly positively charged. As discussed above in Sections A and F, it has been proposed in the present invention that the effect of this region may be mediated by its formation of electrostatic bonds with PAI-1. To test this hypothesis, each of the charged residues within the loop were altered and the effect of these mutations upon the enzyme's interaction with PAI-1 was assessed as described below. If the positively charged residues in the loop form salt bridges with a complementary region of the serine protease inhibitor, PAI-1, then their substitution by negatively charged residues would be expected to be disruptive of interactions between t-PA and PAI-1 due to the juxtaposition of the side chains of similarly charged residues during the association of these two proteins.

[0095]    More specifically, site directed mutagenesis was carried out as described above in Section B and used to construct cDNAs that encoded t-PA mutants in which $Lys_{296}$, $Arg_{298}$, or $Arg_{299}$ had been replaced by a Glu residue. A cDNA encoding a triple mutant of t-PA in which all three of these residues were replaced by Glu was also constructed. Two additional cDNA's were produced; one encodes a t-PA mutant in which $His_{297}$ has been replaced by a Tyr residue while the other encodes an enzyme in which $Pro_{301}$ has been replaced by Gly.

[0096]    The sequences of the six mutagenic primers employed to construct these t-PA mutants were:

$$t\text{-PA}(K_{296}{\rightarrow}E) : 5'\text{-ATCTTTGCCGAGCACAGGA-3'}$$

t-PA(H$_{297}$->Y) : 5´-TTTGCCAAGTACAGGAGGT-3´

t-PA(R$_{298}$->E) : 5´-GCCAAGCACGAGAGGTCGCCC-3´

t-PA(R$_{299}$->E) : 5´-AAGCACAGGGAGTCGCCCGG-3´

t-PA(P$_{301}$->G) : 5´-AGGAGGTCGGGCGGAGAGCG-3´

t-PA(K$_{296}$, R$_{298}$, R$_{299}$->

E, E, E) :

5´-GCCATCTTTGCCGAGCACGAGGAGTCGCCCGGAGA-3´

[0097]  cDNAs encoding the mutated enzymes t-PA(K$_{296}$→E), t-PA(H$_{297}$→Y), t-PA(R$_{298}$→E) and t-PA(P$_{301}$→G) were ligated into the transient expression vector pSVT7(RI⁻), as described above.

[0098]  cDNAs encoding the mutated enzymes t-PA(K$_{296}$, R$_{298}$, R$_{299}$ → E, E, E) and t-PA(R$_{299}$→E) were ligated into the transient expression vector pSTE. pSTE is a derivative of pSVT7 and was constructed by replacement of the 350 bp ClaI-HindIII promoter/origin fragment of pSTV7 with the 418 bp HpaII-HindIII fragment from the promoter/origin region of SV40 cs1085 (DiMaio, D. et al, J. Mol. Biol., 140:129-142 (1980)).

[0099]  The resulting plasmids were designated pSVT7(RI⁻)/t-PA(K$_{296}$→E), pSVT7(RI⁻)/t-PA(H$_{297}$→Y); pSVT7(RI⁻)/t-PA(R$_{298}$→E); pSTE/t-PA(R$_{299}$→E); pSVT7(RI⁻)/t-PA(R$_{301}$→G); and pSTE/t-PA(K$_{296}$, R$_{298}$, R$_{299}$→E, E, E).

[0100]  E. coli strain DH-1 (Hanahan, D. et al, DNA Cloning, Volume 1, Ed. Glover, D.M., I.R.L. Press, Oxford, pages 109-135 (1985)) was transformed with the above mutant plasmids and the resulting strains were designated pSVT7 (RI⁻)/t-PA(K$_{296}$→E) [DH-1],

pSVT7(RI⁻)/t-PA(R$_{297}$→Y) [DH-1];
pSVT7(RI⁻)/t-PA(R$_{298}$→E) [DH-1];
pSTE/t-PA(R$_{299}$→E) [DH-1];
pSVT7(RI⁻)/t-PA(R$_{301}$→G) [DH-1]; and pSTE/t-PA(K$_{296}$, R$_{298}$, R$_{299}$→E, E, E) [DH-1], respectively. The presence of the correct fragment was confirmed by hybridization to the appropriate radiolabeled mutagenic oligonucleotide and the orientation of the fragment was verified by restriction mapping and DNA sequencing, using the appropriate mutagenic oligonucleotides as primers.

[0101]  pSVT7(RI⁻)/t-PA(R$_{298}$→E) [DH-1];
pSTE/t-PA(R$_{299}$→E) [DH-1]; and pSTE/t-PA(K$_{296}$, R$_{298}$, R$_{299}$→E, E, E) [DH-1] have been deposited at the American Type Culture Collection under ATCC Nos. 68157, 68154, and 68153, respectively.

[0102]  The above plasmid DNAs were then used to transfect COS cells as described above. Assays were performed as described above with both dilutions of the resulting conditioned media (typically 1:300) and with immuno-purified enzymes.

[0103]  Next, the K$_m$ and K$_{cat}$ values of the wild-type and mutant t-PAs were determined by assaying the various forms of the enzyme in the presence of saturating concentrations of Des-A-fibrinogen (25 µg/ml) and different concentrations (from 0.02-0.16 µM) of the substrate, Lys-plasminogen. The results are shown in Table XI below.

Table XI

| Enzyme | K$_m$(µM) | K$_{cat}$(s$^{-1}$) |
|---|---|---|
| Wild-type t-PA | 0.024 | 0.22 |

Table XI   (continued)

| Enzyme | $K_m(\mu M)$ | $K_{cat}(s^{-1})$ |
|---|---|---|
| t-PA($K_{296} \rightarrow$E) | 0.026 | 0.22 |
| t-PA($H_{297} \rightarrow$Y) | 0.017 | 0.14 |
| t-PA($R_{298} \rightarrow$E) | 0.027 | 0.24 |
| t-PA($R_{299} \rightarrow$E) | 0.033 | 0.26 |
| t-PA($P_{301} \rightarrow$G) | 0.027 | 0.24 |
| t-PA($K_{296}$, $R_{298}$, $R_{299} \rightarrow$ E, E, E) | 0.027 | 0.24 |

[0104]   As shown in Table XI above, none of the mutations discussed above substantially altered the t-PA's interaction with its substrate.

[0105]   Similarly, the data presented in Figure 6. suggests that the mutations have not altered t-PA's interaction with its positive effector, Des-A-fibrinogen. By contrast, the data presented in Figure 7 indicates clear differences in the behavior of wild-type t-PA and some of the mutant t-PAs. Specifically, the ability to interact normally with the serpin, PAI-1, has been substantially changed for three of the mutant t-PAs, i.e., t-PA( $R_{298} \rightarrow$E), t-PA($R_{299} \rightarrow$E), and t-PA($K_{296}$, $R_{298}$, $R_{299} \rightarrow$E, E, E). The behavior of the triple mutant is particularly striking; even after pre-incubation with a greater than 200-fold molar excess of PAI-1, the triple mutant shows no loss of activity. These findings support the proposal that the surface loop of t-PA, i.e., residues 296-302, interacts specifically with the cognate inhibitor, PAI-1, and suggest that this interaction involves $Arg_{298}$ and $Arg_{299}$. These observations are consistent with the hypothesis that the specific interactions between t-PA and PAI-1 involve electrostatic bonds. The residues of t-PA involved in these interactions are $Arg_{298}$, $Arg_{299}$, and $Arg_{304}$.

## Claims

1. A t-PA mutant which is resistant to inhibition by its cognate inhibitor wherein in said t-PA mutant at least one of the basic amino acid at position 298 of human t-PA and the basic amino acid at position 299 of human t-PA has been replaced by an acidic or neutral amino acid.

2. A t-PA mutant as claimed in claim 1 wherein in said t-PA mutant the basic amino acid at position 296 of human t-PA has also been replaced by an acidic or neutral amino acid.

3. A t-PA mutant as claimed in claim 2 wherein in said mutant the basic amino acid at each of positions 296, 297, 298 and 299 of human t-PA have been replaced by an acidic or neutral amino acid.

4. A t-PA mutant as claimed in any one of the preceding claims wherein said cognate inhibitor is selected from PAI-1, PAI-2 and PAI-3.

5. A gene encoding a t-PA mutant as claimed in any one of the preceding claims.

6. A method for obtaining a t-PA mutant which is resistant to inhibition by its cognate inhibitor comprising:

    (A) culturing a host cell with DNA comprising a gene as claimed in claim 5; and
    (B) isolating the resulting t-PA mutant.

7. A method for providing a t-PA mutant as claimed in any one of claims 1 to 4 comprising:

    (A) obtaining a t-PA mutant wherein at least one of the basic amino acid at position 298 of human t-PA and the basic amino acid at position 299 of human t-PA has been replaced by an acidic or neutral amino acid; and
    (B) screening for a t-PA mutant which is resistant to inhibition by its cognate inhibitor.

8. E.coli pSVT(R1⁻)/t-PA($R_{298} \rightarrow$E) [DH-1] having ATCC deposit No.68157 or

    E.coli pSTE/t-PA ($R_{299} \rightarrow$E) [DH-1] having ATCC deposit No. 68154, or
    E.coli pSTE/t-PA ($K_{296}$, $R_{298}$, $R_{299} \rightarrow$E,E,E) [DH-1] having ATCC deposit No. 68153

9.  Plasmid pSVT7(R1⁻)/t-PA(R$_{298}$→E) present in E.coli pSTV7(R1⁻)/t-PA (R$_{298}$→E) [DH-1] having ATCC deposit No. 68157 or

plasmid pSTE/t-PA (R$_{299}$→E) present in E.coli pSTE/t-PA (R$_{299}$→E) [DH-1] having ATCC deposit No. 68154 or plasmid pSTE/t-PA (K$_{296}$, R$_{298}$, R$_{299}$→E,E,E) present in E.coli pSTE/t-PA (K$_{296}$, R$_{298}$, R$_{299}$→E,E,E) [DH-1] having ATCC deposit No. 68153

**Patentansprüche**

1.  t-PA-Mutante, die gegenüber der Inhibition durch ihren zugehörigen Inhibitor resistent ist, wobei in der t-PA-Mutante wenigstens eine der basischen Aminosäuren an Position 298 und 299 des humanen t-PA durch eine saure oder neutrale Aminosäure ersetzt wurde.

2.  t-PA-Mutante nach Anspruch 1, dadurch **gekennzeichnet**, dass in der t-PA-Mutante auch die basische Aminosäure an Position 296 des humanen t-PA durch eine saure oder neutrale Aminosäure ersetzt wurde.

3.  t-PA-Mutante nach Anspruch 2, dadurch **gekennzeichnet**, dass in der Mutante die basische Aminosäure an jeder der Positionen 296, 297, 298 und 299 des humanen t-PA durch eine saure oder neutrale Aminosäure ersetzt wurde.

4.  t-PA-Mutante nach einem der vorangegangenen Ansprüche, dadurch **gekennzeichnet**, dass der zugehörige Inhibitor ausgewählt ist aus PAI-1, PAI-2 und PAI-3.

5.  Gen, das für eine wie in einem der vorangegangenen Ansprüche beanspruchte t-PA-Mutante codiert.

6.  Verfahren zum Erhalt einer t-PA-Mutante, die gegenüber einer Inhibition durch ihren zugehörigen Inhibitor resistent ist, umfassend die folgenden Stufen:

    (A) Kultivieren einer Wirtszelle mit einer DNA, die ein wie in Anspruch 5 beanspruchtes Gen umfasst; und

    (B) Isolieren der entstandenen t-PA-Mutante.

7.  Verfahren zum Bereitstellen einer wie in einem der Ansprüche 1 bis 4 beanspruchten t-PA-Mutante, umfassend die folgenden Stufen:

    (A) Erhalt einer t-PA-Mutante, bei der wenigstens eine der basischen Aminosäuren an Position 298 und 299 des humanen t-PA durch eine saure oder neutrale Aminosäure ersetzt wurde; und

    (B) Durchmustern im Hinblick auf eine t-PA-Mutante, die gegenüber der Inhibition durch ihren zugehörigen Inhibitor resistent ist.

8.  E. coli pSVT(R1⁻)/t-PA(R$_{298}$→E)[DH-1] mit der ATCC-Hinterlegungsnummer 68157 oder

    E. coli pSTE/t-PA(R$_{299}$→E) [DH-1] mit der ATCC-Hinterlegungsnummer 68154 oder E. coli pSTE/t-PA(K$_{296}$,R$_{298}$,R$_{299}$→E,E,E) [DH-1] mit der ATCC-Hinterlegungsnummer 68153.

9.  Plasmid pSVT7 (R1⁻)/t-PA(R$_{298}$→E), vorhanden in E. coli pSVT7 (R1⁻) /t-PA(R$_{298}$→E) [DH-1] mit der ATCC-Hinterlegungsnummer 68157 oder

    Plasmid pSTE/t-PA(R→E), vorhanden in E. coli pSTE/t-PA(R$_{299}$→E)[DH-1] mit der ATCC-Hinterlegungsnummer 68154 oder Plasmid pSTE/t-PA(K$_{296}$,R$_{298}$,R$_{299}$→E,E,E), vorhanden in E. coli pSTE/t-PA(K$_{296}$,R$_{298}$,R$_{299}$→E,E,E)[DH-1] mit der ATCC-Hinterlegungsnummer 68153.

**Revendications**

1.  Mutant de t-PA qui est résistant à une inhibition par son inhibiteur apparenté, dans lequel, dans ledit mutant de t-

PA, au moins l'un parmi l'acide aminé basique en position 298 de la t-PA humaine et l'acide aminé basique en position 299 de la t-PA humaine a été remplacé par un acide aminé acide ou neutre.

2. Mutant de t-PA selon la revendication 1, dans lequel, dans ledit mutant de t-PA, l'acide aminé basique en position 296 de la t-PA humaine a aussi été remplacé par un acide aminé acide ou neutre.

3. Mutant de t-PA selon la revendication 2, dans lequel, dans ledit mutant, l'acide aminé basique en chacune des positions 296, 297, 298 et 299 de la t-PA humaine a été remplacé par un acide aminé acide ou neutre.

4. Mutant de t-PA selon l'une quelconque des revendications précédentes, dans lequel ledit inhibiteur apparenté est choisi parmi PAI-1, PAI-2 et PAI-3.

5. Gène codant un mutant de t-PA tel que revendiqué dans l'une quelconque des revendications précédentes.

6. Procédé pour obtenir un mutant de t-PA qui est résistant à une inhibition par son inhibiteur apparenté, comprenant :

(A) la culture d'une cellule hôte avec un ADN comprenant un gène tel que revendiqué dans la revendication 5 ; et
(B) l'isolation du mutant de t-PA résultant.

7. Procédé pour réaliser un mutant de t-PA tel que revendiqué dans l'une quelconque des revendications 1 à 4, comprenant :

(A) l'obtention d'un mutant de t-PA dans lequel au moins l'un parmi l'acide aminé basique en position 298 de la t-PA humaine et l'acide aminé basique en position 299 de la t-PA humaine a été remplacé par un acide aminé acide ou neutre ; et
(B) le dépistage d'un mutant de t-PA qui est résistant à une inhibition par son inhibiteur apparenté.

8. E. coli pSVT(R1⁻)/t-PA($R_{298}\rightarrow$E) [DH-1] ayant le numéro de dépôt ATCC N° 68157 ou

E. coli pSTE/t-PA($R_{299}\rightarrow$E) [DH-1] ayant le numéro de dépôt ATCC N° 68154 ou
E. coli pSTE/t-PA($K_{296},R_{298},R_{299}\rightarrow$E,E,E) [DH-1] ayant le numéro de dépôt ATCC N° 68153.

9. Plasmide pSVT7 (R1⁻)/t-PA ($R_{298}\rightarrow$E) présent dans E. coli pSVT7 (R1⁻) /t-PA ($R_{298}\rightarrow$E) [DH-1] ayant le numéro de dépôt ATCC 68157 ou

plasmide pSTE/t-PA ($R_{299}\rightarrow$E) présent dans E. coli pSTE/t-PA($R_{299}\rightarrow$E) [DH-1] ayant le numéro de dépôt ATCC N° 68154 ou
plasmide pSTE/t-PA($K_{296},R_{298},R_{299}\rightarrow$E,E,E) présent dans E. coli pSTE/t-PA($K_{296},R_{298},R_{299}\rightarrow$E,E,E) [DH-1] ayant le numéro de dépôt ATCC N° 68153.

## Figure 1

```
                          16  ·                              39          50
TRYPSIN         . . . . . . . . . .  IVGGYTCGAN  TVPYQVSLNS  . . . . . . .GYH  FCGGSLINSQ
                                                 296    302
TPA LT.CHAIN    . . . . . . . . . .  IKGGLFADIA  SHPWQAAIFA  KHRRSPGERF  LCGGILISSC
UROKINASE       . . . . . . . . . .  IGGEFTTIEN  Q.PWFAAIYR  RHRGGS.VTY  VCGGSLMSPC
PLASMIN         . . . . . . . . . .  VVGGCVAHPH  SWPWQVSLRT  . . . . .RFGMH  FCGGTLISPE
PROTEIN C       DQEDQVDPRL  IDGKMTRRGD  S.PWQVVLLD  . . . . .SKKKL  ACGAVLIHPS
THROMBIN        . . . . . . . . . .  IVEGQDAEVG  LSPWQVMLFR  . . . .KSPQEL  LCGASLISDR

                     57
TRYPSIN         WVVSAAHCYK  S. . . . .GIQV  RLGEDNINVV  EG.NEQFISA  SKSIVH. . . .
                     322
TPA LT. CHAIN   WILSAAHCFQ  ERFPPHHLTV  ILGR.TYRVV  PGEEEQKFEV  EKYIVHK. . .
UROKINASE       WVISATHCFI  DYPKKEDYIV  YLGR.SRLNS  NTQGEMKFEV  ENLILHK. . .
PLASMIN         WVLTAAHCLE  KSPRPSSYKV  ILGA.HQEVN  LEPHVQEIEV  SRLFL. . . . .
PROTEIN C       WVLTAAHCMD  ESKKLL. . .V  RLGEYDLRRW  EKWEL.DLDI  KEVFVH. . . .
THROMBIN        WVLTAAHCLL  YPPWDK. . .N  FTVDDLLVRI  GKHSRTRYER  KVEKISMLDK

                          102
TRYPSIN         . . . . .PSYNS  NTLNNDIMLI  KLKSA. . . . .  ASLNSRVASI  SLPTSCASAG
                                      371                               400
TPA LT. CHAIN   . . . . . .EFDD  DTYDNDIALL  QLKSDSSRCA  QESSV.VRTV  CLPPADLQLP
UROKINASE       . . . .DYSADT  LABHNDIALL  KIRSKEGRCA  QPSRT.IQTI  CLPSMYNDPQ
PLASMIN         . . . . . . . . . .  EPTRKDIALL  KLSSP. . . . .  AVITDKVIPA  CLPSPNYVVA
PROTEIN C       . . . . .PNYSK  STTDNDIALL  HLAQP. . . . .  ATLSQTIVPI  CLPDSGLAER
THROMBIN        IYIHPRYNWK  ENLDRDIALL  KLKRP. . . . .  IELSDYIHPV  CLPDKQTAAK

                                    150
TRYPSIN         . . . . . .TQCL  ISGWGNTKSS  GT.SYPDVLK  CLKAPILSDS  SCKSAYPGQ.
TPA LT. CHAIN   DW. . . .TECE  LSGYGKHEAL  SP.FYSERLK  EAHVRLYPSS  RCTSQHLLNR
UROKINASE       FG. . . .TSCE  ITGFGKENST  DY.LYPEQLK  MTVVKLISHR  ECQQPHYYGS
PLASMIN         DR. . . .TECF  ITGWGETQGT  . . .FGAGLLK  EAQLPVIENK  VCNRYEFLNG
PROTEIN C       ELNQAGQETL  VTGWGYHSSR  E.KEAKRNRT  FVLNFIKIPV  VPHNECSEVM
THROMBIN        LLH.AGFKGR  VTGWGNRRET  WTTSVAEVQP  SVLQVVNLPL  VERPVCKAST

                                              195    200
TRYPSIN         . . .ITSNMFC  AGYL.EGG. .  . . .KDSCQGD  SGGPVVCS. .  . . . . .GKLQGI
                     450                               478
TPA LT. CHAIN   T. .VTDNMLC  AGDTRSGGPQ  ANLHDACQGD  SGGPLVCLND  . .GRMTLVGI
UROKINASE       E. .VTTKMLC  AAD. . . . .PQ  .WKTDSCQGD  SGGPLVCSLQ  . .GRMTLTGI
PLASMIN         R. .VQSTELC  AGHL. . . . . .  . .ATDSCQGD  SGGPLVCFEK  . .DKYILQGV
PROTEIN C       SNMVSENMLC  AGIL. . . . . .  GDRQDACEGD  SGGPMVASFH  . .GTWFLVGL
THROMBIN        RIRITDNMFC  AGYK. . .PGE  GKRGDACEGD  SGGPFVMKSP  YNNRWYQMGI

                     214                               245
TRYPSIN         VSWGSGCAQK  NKPGVYTKVC  NYVSWIKQTI  ASN. . . . . . . .  . .
                     500                               527
TPA LT. CHAIN   ISWGLGCGQK  DVPGVYTKVT  NYLDWIRDNM  RP. . . . . . . .  . .
UROKINASE       VSWGRGCALK  DKPGVYTRVS  HFLPWIRSHT  KEENGLAL. .  . .
PLASMIN         TSWGLGCARP  NKPGVYVRVS  RFVTWIEGVM  RNN. . . . . . . .  . .
PROTEIN C       VSWGEGCGLL  HNYGVYTKVS  RYLDWIHGHI  RDKEAPQKSW  AP
THROMBIN        VSWGEGCDRD  GKYGFYTHVF  RLKKWIQKVI  DRLGS. . . . .  . .
```

Figure 2

```
PAI-1        .......... .......... .......... .......... ..........
Antitrypsin  .......... .......... .......... .......... ..........

PAI-2        .......... .......... .......... .......... ..........
A-chymotryp  .......... .......... .......... .......... ..........
A2-antiplas  .......... .......... .......... .......... ..........
A-thrombIII  .......... .......... .......... .......... ..........
HeparinCoII  .......... ...GSKGPLD QLEKGGETAQ SADPQWEQLN NKNLSMPLLP
Clinhibitor  NPNATSSSSQ DPESLQDRGE GKVATTVISK MLPVEPILEV SSLPTTNSTT

                                                                   1
PAI-1        .......... .......... .......... .......... ...VHHPPSY
Antitrypsin  .......... .......... .......... .......... ....EDPQGD
                                                                   1
PAI-2        .......... .......... .......... .......... ..........
A-chymotryp  .......... .......... .......... .......... .....NSPLD
A2-antiplas  .......... ... .......NQE QVSPLTLLKL GNQEPGGQTA
A-thrombIII  .......... ....CHGSPV DICTAKPRDI PMNPMCIYRS PEKKATEDEG
HeparinCoII  ADFHKENTVT NDWIPEGEED DDYLDLEKIF SEDDDYIDIV DSLSVSPTDS
Clinhibitor  NSATKITANT TDEPTTQPTT EPTTQPTIQP TQPTTQLPTD SPTQPTTGSF

PAI-1        VAHLA..... .......... ....SDFGVR VFQQVAQ.AS KDRNVVFSPY
Antitrypsin  AAQKTDTSHH DQDHPTFNKI TPNLAEFAFS LYRQLAH.QS NSTNIFFSPV
                                                                   50
PAI-2        .......... ...MEDLCVA NTLFALNLFK HLAK.ASPTQ NLFLSPWSIS
A-chymotryp  EENLTQENQD RGTHVDLGLA SANV.DFAFS LYKQLVL.KA LDKNVIFSPL
A2-antiplas  LKSPPGVCSR DPTPEQTHRL ARAMMAFTAD LFSLVAQ.TS TCPNLILSPL
A-thrombIII  ....SEQKIP EATNRRVWEL SKANSRFATT FYQHLADSKN DNDNIFLSPL
HeparinCoII  DVSAGNILQL FHGKSRIQRL NILMAKPAFN LYRVLKDQVN TFDNIFIAPV
Clinhibitor  CPGPVTLCSD LESHSTEAVL GDALVDFSLK LYHAFSAMKK VETNMAFSPF

                          50
PAI-1        GVASVLAMLQ LTTGGETQQQ IQAAMGPKID D......... ..........
Antitrypsin  SIATAFAMLS LGTKADTHDE ILEGLNFNLT E......... ..........

PAI-2        STMAMVYHGS RGSTEDQMAK VLQFNEVGAN AVTPMTPENF TSCGFMQQIQ
A-chymotryp  SISTALAFLS LGAHNTTLTE ILKASSSPHG D......... ..........
A2-antiplas  SVALALSHLA LGAQNHTLQR LQQVLHAGSG P......... ..........
A-thrombIII  SISTAFAMTK LGACNDTLQQ LMEVFKFDTI SEKTSDQIHF ..........
HeparinCoII  GISTAMGMIS LGLKGETHEQ VHSILHFKDF VN........ ..........
Clinhibitor  SIASLLTQVL LGAGQNTKTN LESILSYPKD FTCVHQALKG F.........

                                                                   100
PAI-1        .......... .......KGM APALRHLYKE LMGPWNKDE. ISTTDAIFVQ
Antitrypsin  .......... ....IPEAQI HEGFQELLRT LNQPDSQLQ. LTTDGGLFLS
                                                    100
PAI-2        KGSYPDAILQ AQAADKIHSS FRSLSSAINA STGDYL.LES VNKLFGEKSA
A-chymotryp  .......... ....LLRQKF TQSFQHLRAP SISSSDELQ. LSMGNAMFVK
A2-antiplas  .......... .......... ..CLPHLLSR LCQDLGPGA. FRLAARHYLQ
A-thrombIII  .......... .......... ..FFAKLNCR LYRKANKSSK LVSANRLFGD
HeparinCoII  .......... ASSKYEITTI HNLFRKLTHR LFRRNFGYT. LRSVNDLYIQ
Clinhibitor  .......... .......... .......... .......TTKG VTSVSQIFHS

PAI-1        RDLKLVQGFM PHFFRLFRST VKQVDFSE.V ERARFIINDW VKTHTKGMIS
Antitrypsin  EGLKLVDKFL EDVKKLYHSE AFTVNFGD.T EEAKKQINDY VEKGTQGKIV
                                        .        150
PAI-2        SFREEYIRLC QKYYSSEPQA VDFLECAEEA RKKINSWVKT QTKGKIPNLL
A-chymotryp  EQLSLLDRFT EDAKRLYGSE AFATDFQD.S AAARKLINDY VKNGTRGKIT
A2-antiplas  KGFPIKEDFL EQSEQLFGAK ..PVSLTGKQ EDDLANIMQW VKEATEGKIQ
A-thrombIII  KSLTFNETYQ DISELVYGAK LQPLDFKENA EQSRAAIHKW VSNKTEGRIT
HeparinCoII  KQFPILLDFK TKVREYYFAE AQIADFSD.. PAFISKTNNH IHELTKGLIK
Clinhibitor  PDLAIRDTFV NASRTLYSSS PRVLSNNS.. DANLELINTW VAKNTNNKIS
```

Figure 2 cont.

```
          150
PAI-1       NLLGKGAVDQ LTRLVLVNAL YFNGQWKTPF PDSSTHRRLF HKSDGSTVSV
Antitrypsin DLV..KELDR DTVFALVNYI FFKGKWERPF EVKDTEEEDF HVDQVTTVKV
                                                     200
PAI-2       PEGSVDGDTR MVLVNAVYFK GKWKTPPEKK LNGLYPFRVN SAQRTPVQMM
A-chymotryp DLI..KDPDS QTMMVLVNYI FFKAKWEMPF DPQDTHQSRF YLSKKKWVMV
A2-antiplas EPLS..GLPE DTVLLLLNAI HFQGFWRNKF DPSLTQRDSF HLDEQFTVPV
A-thrombIII DVIPSEAINE LTVLVLVNTI YFKGLWKSKF SPENTRKELF YKADGESCSA
HeparinCoII DALE..NIDP ATQMMILNCI YFKGSWVNKF PVEMTHNENF RLNEREVVKV
Clinhibitor RLLD..SLPS DTRLVLLNAI YLSAKWKTTF DPKKTRMEPF HFKNSVIKVP
```

```
          200
PAI-1       PMMAQTNKFN YTEFTTPDGH YYDILELPYE GDTLSMFIAA PYEKE..VPL
Antitrypsin PMMKRLGMFN IQHC.KKLSS W..VLLMKYL GNANAIFFLP DEGK.....L
                                                     250
PAI-2       YLREKLNIGY IEDLKAQ... ILELPYAGDV SMFLLLPDEI ADVSTGLELL
A-chymotryp PMMSLHHLTI PYFRDEELSC ..TVVELKYT GNASALFILP DQDK.....M
A2-antiplas EMMQARTYPL RWFLLEQPEI ..QVAHFPFK NNMSFVVLVP TH.....FEW
A-thrombIII SMNYQEGKFR YRR..VAEGT ..QVLELPFK GDDITMVLIL PK.....PEK
HeparinCoII SMMQTKGNFL AANDQELDCD ...ILQLEYV GGISMLIVVP HKM....SGR
Clinhibitor MMNSKKYPVA HFIDQTLKAK .VGQLQL..S HNLSLVILVP QNLK...HRL
```

```
          250
PAI-1       SALTNILSAQ LISHWKGNMT ..RLPRLLVL PKFSLETEVD LR.KPLENLG
Antitrypsin QHLENELTHD IITKFLENED ..RRSASLHL PKLSITGTYD LK.SVLGQLG
                                                     300
PAI-2       ESEITYDKLN KWTSKDKMAE DEVEVYIPQF KLEEHYELR. SILRSMGMED
A-chymotryp EEVEAKLLPE TLKRWRDSLE F.REIGELYL PKFSISRDYN LN.DILLQLG
A2-antiplas NVSQVLANLS WDTLHPPLVW ..ERPTKVRL PKLYLKHQMD LV.ATLSQLG
A-thrombIII SLAKVEKELT PEVLQEWLDE LEEMMLVVHM PRFRIEDGFS LK.EQLQDMG
HeparinCoII KTLEAQLTPR VVERWQKSMT ..NRTREVLL PKFKLEKNYN LV.ESLKLMG
Clinhibitor EDMEQALSPS VFKAIMEKLE MSKFQPTLLT LPRIKVTTSQ DMLSIMEKLE
```

```
          300
PAI-1       MTDMFRQ... FQADFTSLSD QEPLHVAQAL QKVKIEVNES GTVASSST..
Antitrypsin ITKVPSN... .GADLSGVTE EAPLKLSKAV HKAVLTIDER GTEAAGAM..
                                                     350
PAI-2       AFNK...GRA NFSGMSERND LFLSEVFHQA MVDVNEEGTE AAAGTGGV..
A-chymotryp IEEAFTS... .RADLSGITG ARNLAVSQVV HKVVSDVFEE GTEASAAT..
A2-antiplas LQELPQA... ..PDLRGISE Q.SLVVSGVQ HQSTLELSEV GVEAAAAT..
A-thrombIII LVDLFSPEKS KLPGIVAEGR D.DLYVSDAF HKAFLEVNEE GSEAAAST..
HeparinCoII IRMLFD..... .KNGNMAGIS DQRIAIDLFK HQGTITVNEE GTQATTVT..
Clinhibitor FFDFSYD... ..LNLCGLTE DPDLQVSAMQ HQTVLELTET GVEAAAAS..
```

```
          350
PAI-1       AVIVSARMAP EE....IIMD RPFLFVVREN PTGTVLFMGQ VMEP......
Antitrypsin FLEAIPMSIP PE....VKFN KPFVFLMIEQ NTKSPLFMGK VVNPTQK...

PAI-2       ...MTGRTGH GGPQ..FVAD HPFLFLIMHK ITKCILFFGR FCSF......
A-chymotryp AVKITLLSAL VETRTIVRFN RPFLMIIVPT DTQNIFFMSK VTNP.SKPRA
A2-antiplas .SIAMSRMSL SS....FSVN RPFLFFIFED TTGLPLFVGS VRNPNPSAPR
A-thrombIII AVVIAGRSLN PNRVT.FKAN RPFLVFIREV PLNTIIFMGR VANPCVK...
HeparinCoII TVGFMFLSTQ VR....PTVD RPFLFLIYEH RTSCLLFMGR VANPSRS...
Clinhibitor .AISVARTLL V.....FEVQ QPFLFVLWDQ QHKFFVFMGR VYDPRA....
```

```
PAI-1       .......... .......... .......... .......... .........
Antitrypsin .......... .......... .......... .......... .........

PAI-2       .......... .......... .......... .......... .........
A-chymotryp CIKQWGSQ.. .......... .......... .......... .........
A2-antiplas ELKEQQDSPG NKDFLQSLKG FPRGDKLFGP DLKLVFPMEK DYPQFGSPK
A-thrombIII .......... .......... .......... .......... .........
HeparinCoII .......... .......... .......... .......... .........
Clinhibitor .......... .......... .......... .......... .........
```

Figure 3

figure 4

Figure 5

Figure 6

Figure 7



Active PAI-1 (fmol)

Figure 8